Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · colon-landscapes@1

SRR12475141

—

840daddc-c16c-59af-97f0-7f3bb6c0466a

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • MYC_TARGETS_V2+0.520
  • INTERFERON_ALPHA_RESPONSE+0.390
  • INTERFERON_GAMMA_RESPONSE+0.330
  • ALLOGRAFT_REJECTION+0.290
  • NOTCH_SIGNALING+0.260
  • TNFA_SIGNALING_VIA_NFKB+0.250
  • E2F_TARGETS+0.240
  • P53_PATHWAY+0.220
  • DNA_REPAIR+0.190
  • REACTIVE_OXYGEN_SPECIES_PATHWAY+0.190

Top 10 suppressed

  • PROTEIN_SECRETION-0.480
  • ANDROGEN_RESPONSE-0.370
  • BILE_ACID_METABOLISM-0.370
  • TGF_BETA_SIGNALING-0.310
  • UV_RESPONSE_DN-0.260
  • HEME_METABOLISM-0.230
  • PEROXISOME-0.210
  • PANCREAS_BETA_CELLS-0.190
  • ANGIOGENESIS-0.110
  • KRAS_SIGNALING_UP-0.100

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1c4779698-5c81-4eed-80ac-80fdd47f658b
colon-landscapes@1
——0.838
2SRR4195685
colon-landscapes@1
——0.796
3TCGA-22-5471-01A-01R-1635-07
lung-landscapes@6
—cohortSQ20.775
4TCGA-E9-A3QA-01A-61R-A22K-07
breast-umap@18
—D0.752
5TCGA-A7-A6VW-01A-21R-A33J-07
breast-umap@18
—E0.751
6301853fd-348d-4a99-9625-7da725023c1d
colon-landscapes@1
——0.737
7R61
bladder-landscape@3
——0.736
8MNG153
mng-umap@100
——0.734
9TCGA-LL-A8F5-01A-11R-A36F-07
breast-umap@18
—E0.725
10TCGA-OL-A66I-01A-21R-A29R-07
breast-umap@18
—D0.723

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 32 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
MYC_TARGETS_V20.520Idelalisib— uncovered
INTERFERON_ALPHA_RESPONSE0.390Inavolisib— uncovered
INTERFERON_GAMMA_RESPONSE0.330Idelalisib— uncovered
ALLOGRAFT_REJECTION0.290Idelalisib— uncovered
NOTCH_SIGNALING0.260Inavolisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.250Inavolisib— uncovered
E2F_TARGETS0.240Inavolisib— uncovered
P53_PATHWAY0.220Idelalisib— uncovered
DNA_REPAIR0.190Idelalisib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.190Inavolisib— uncovered
IL6_JAK_STAT3_SIGNALING0.180Inavolisib— uncovered
G2M_CHECKPOINT0.160Inavolisib— uncovered
MYOGENESIS0.140Inavolisib— uncovered
UV_RESPONSE_UP0.140Idelalisib— uncovered
APICAL_JUNCTION0.120Inavolisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.120Inavolisib— uncovered
HEDGEHOG_SIGNALING0.120Inavolisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.120Inavolisib— uncovered
APICAL_SURFACE0.090Temsirolimus— uncovered
CHOLESTEROL_HOMEOSTASIS0.090Remibrutinib— uncovered